Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2024 07:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson’s Disease Patients Event Will Be Held on Monday, September 30, 2024, at...
September 19, 2024 07:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
September 03, 2024 07:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
August 29, 2024 07:30 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

Results Include Safety, Tolerability, Pharmacokinetics, and Target Engagement GT-02287, in Development for GBA1 Parkinson’s Disease, on Track to Initiate Phase 1b Trial in Patients in Q4 2024 ...
August 08, 2024 07:30 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation of Phase 1b Study of GT-02287 in...
August 01, 2024 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

BETHESDA, Md. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
June 28, 2024 16:39 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
June 27, 2024 16:08 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Mr. Mack is the Company’s Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics,...
June 27, 2024 08:35 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease

BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
June 25, 2024 07:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...